Engel Law PLLC is investigating whether fair value to Provention shareholders will result from the proposed sale of Provention Bio, Inc. (NASDAQ: PRVB) to Sanofi for $25.00 per share.
The Firm’s investigation concerns:
(i) whether Provention’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the $25.00 per share merger consideration adequately compensates Provention’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.